BACKGROUND:Mammographic breast density is a strong risk factor for breast cancer. Tamoxifen, which reduces the risk of breast cancer in women at high risk, also reduces mammographic breast density. However, it is not known if tamoxifen-induced reductions in breast density can be used to identify women who will benefit the most from prophylactic treatment with this drug. METHODS: We conducted a nested case-control study within the first International Breast Cancer Intervention Study, a randomized prevention trial of tamoxifen vs placebo. Mammographic breast density was assessed visually and expressed as a percentage of the total breast area in 5% increments. Case subjects were 123 women diagnosed with breast cancer at or after their first follow-up mammogram, which took place 12-18 months after trial entry, and control subjects were 942 women without breast cancer. Multivariable logistic regression was used to adjust for other risk factors. All statistical tests were two-sided. RESULTS: In the tamoxifen arm, 46% of women had a 10% or greater reduction in breast density at their 12- to 18-month mammogram. Compared with all women in the placebo group, women in the tamoxifen group who experienced a 10% or greater reduction in breast density had 63% reduction in breast cancer risk (odds ratio = 0.37, 95% confidence interval = 0.20 to 0.69, P = .002), whereas those who took tamoxifen but experienced less than a 10% reduction in breast density had no risk reduction (odds ratio = 1.13, 95% confidence interval = 0.72 to 1.77, P = .60). In the placebo arm, there was no statistically significant difference in breast cancer risk between subjects who experienced less than a 10% reduction in mammographic density and subjects who experienced a greater reduction. CONCLUSION: The 12- to 18-month change in mammographic breast density is an excellent predictor of response to tamoxifen in the preventive setting.
RCT Entities:
BACKGROUND: Mammographic breast density is a strong risk factor for breast cancer. Tamoxifen, which reduces the risk of breast cancer in women at high risk, also reduces mammographic breast density. However, it is not known if tamoxifen-induced reductions in breast density can be used to identify women who will benefit the most from prophylactic treatment with this drug. METHODS: We conducted a nested case-control study within the first International Breast Cancer Intervention Study, a randomized prevention trial of tamoxifen vs placebo. Mammographic breast density was assessed visually and expressed as a percentage of the total breast area in 5% increments. Case subjects were 123 women diagnosed with breast cancer at or after their first follow-up mammogram, which took place 12-18 months after trial entry, and control subjects were 942 women without breast cancer. Multivariable logistic regression was used to adjust for other risk factors. All statistical tests were two-sided. RESULTS: In the tamoxifen arm, 46% of women had a 10% or greater reduction in breast density at their 12- to 18-month mammogram. Compared with all women in the placebo group, women in the tamoxifen group who experienced a 10% or greater reduction in breast density had 63% reduction in breast cancer risk (odds ratio = 0.37, 95% confidence interval = 0.20 to 0.69, P = .002), whereas those who took tamoxifen but experienced less than a 10% reduction in breast density had no risk reduction (odds ratio = 1.13, 95% confidence interval = 0.72 to 1.77, P = .60). In the placebo arm, there was no statistically significant difference in breast cancer risk between subjects who experienced less than a 10% reduction in mammographic density and subjects who experienced a greater reduction. CONCLUSION: The 12- to 18-month change in mammographic breast density is an excellent predictor of response to tamoxifen in the preventive setting.
Authors: Rosa Anna DeFilippis; Hang Chang; Nancy Dumont; Joseph T Rabban; Yunn-Yi Chen; Gerald V Fontenay; Hal K Berman; Mona L Gauthier; Jianxin Zhao; Donglei Hu; James J Marx; Judy A Tjoe; Elad Ziv; Maria Febbraio; Karla Kerlikowske; Bahram Parvin; Thea D Tlsty Journal: Cancer Discov Date: 2012-07-09 Impact factor: 39.397
Authors: Valerie A McCormack; Anya Burton; Isabel dos-Santos-Silva; John H Hipwell; Caroline Dickens; Dorria Salem; Rasha Kamal; Mikael Hartman; Charmaine Pei Ling Lee; Kee-Seng Chia; Vahit Ozmen; Mustafa Erkin Aribal; Anath Arzee Flugelman; Martín Lajous; Ruy Lopez-Riduara; Megan Rice; Isabelle Romieu; Giske Ursin; Samera Qureshi; Huiyan Ma; Eunjung Lee; Carla H van Gils; Johanna O P Wanders; Sudhir Vinayak; Rose Ndumia; Steve Allen; Sarah Vinnicombe; Sue Moss; Jong Won Lee; Jisun Kim; Ana Pereira; Maria Luisa Garmendia; Reza Sirous; Mehri Sirous; Beata Peplonska; Agnieszka Bukowska; Rulla M Tamimi; Kimberly Bertrand; Chisato Nagata; Ava Kwong; Celine Vachon; Christopher Scott; Beatriz Perez-Gomez; Marina Pollan; Gertraud Maskarinec; Graham Giles; John Hopper; Jennifer Stone; Nadia Rajaram; Soo-Hwang Teo; Shivaani Mariapun; Martin J Yaffe; Joachim Schüz; Anna M Chiarelli; Linda Linton; Norman F Boyd Journal: Cancer Epidemiol Date: 2015-12-24 Impact factor: 2.984
Authors: Ernest U Ekpo; Mark F McEntee; Mary Rickard; Patrick C Brennan; Jyotsna Kunduri; Delgermaa Demchig; Claudia Mello-Thoms Journal: Br J Radiol Date: 2016-02-16 Impact factor: 3.039
Authors: Katherine D Crew; Garnet L Anderson; Dawn L Hershman; Mary Beth Terry; Parisa Tehranifar; Danika L Lew; Monica Yee; Eric A Brown; Sebastien S Kairouz; Nafisa Kuwajerwala; Therese Bevers; John E Doster; Corrine Zarwan; Laura Kruper; Lori M Minasian; Leslie Ford; Banu Arun; Marian Neuhouser; Gary E Goodman; Powel H Brown Journal: Cancer Prev Res (Phila) Date: 2019-05-28
Authors: C C Hack; L Häberle; K Geisler; R Schulz-Wendtland; A Hartmann; P A Fasching; M Uder; D L Wachter; S M Jud; C R Loehberg; M P Lux; C Rauh; M W Beckmann; K Heusinger Journal: Geburtshilfe Frauenheilkd Date: 2013-02 Impact factor: 2.915
Authors: Michael P Lisanti; Aristotelis Tsirigos; Stephanos Pavlides; Kimberley Jayne Reeves; Maria Peiris-Pagès; Amy L Chadwick; Rosa Sanchez-Alvarez; Rebecca Lamb; Anthony Howell; Ubaldo E Martinez-Outschoorn; Federica Sotgia Journal: Cell Cycle Date: 2013-12-05 Impact factor: 4.534
Authors: Cynthia A Thomson; H H Sherry Chow; Betsy C Wertheim; Denise J Roe; Alison Stopeck; Gertraud Maskarinec; Maria Altbach; Pavani Chalasani; Chuan Huang; Meghan B Strom; Jean-Philippe Galons; Patricia A Thompson Journal: Breast Cancer Res Treat Date: 2017-05-30 Impact factor: 4.872
Authors: Laurel A Habel; Weiva Sieh; Russell B McBride; Kezhen Fei; Joseph H Rothstein; Stacey E Alexeeff; Xiaoyu Song; Lori C Sakoda; Valerie McGuire; Ninah Achacoso; Luana Acton; Rhea Y Liang; Jafi A Lipson; Martin J Yaffe; Daniel L Rubin; Alice S Whittemore Journal: Cancer Epidemiol Biomarkers Prev Date: 2020-02-17 Impact factor: 4.254